Publications by authors named "Stephen Loucian Lowe"
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
Alzheimers Dement (N Y)
February 2021
Article Synopsis
- The study evaluated the safety and tolerability of donanemab, a potential Alzheimer's treatment, in patients with mild cognitive impairment or mild to moderate dementia.
- Participants received varying single and multiple doses of donanemab, followed by monitoring periods to assess outcomes and safety.
- Results indicated that donanemab was well tolerated at doses up to 10 mg/kg and effectively reduced amyloid deposits, notably achieving a 40-50% reduction at the highest dose, despite a shorter half-life than anticipated.
Background: Diabetes is reported to be linked to poorer cognitive function. The purpose of this study is to examine (a) clinical correlation between cognitive function and the biochemical perturbations in T2DM, and (b) the impact of statin treatment on cognitive function in diabetic subjects.
Methods: Forty Singaporean Chinese males with diabetes and twenty Singaporean Chinese males without diabetes were recruited for this study.